Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Modelling the Cancer Phenotype in the Era of CRISPR-Cas9 Gene Editing.

Stewart J, Banerjee S, Pettitt SJ, Lord CJ.

Clin Oncol (R Coll Radiol). 2019 Oct 31. pii: S0936-6555(19)30438-8. doi: 10.1016/j.clon.2019.09.057. [Epub ahead of print] No abstract available.

PMID:
31679912
2.

Longitudinal analysis of a secondary BRCA2 mutation using digital droplet PCR.

Khalique S, Pettitt SJ, Kelly G, Tunariu N, Natrajan R, Banerjee S, Lord CJ.

J Pathol Clin Res. 2019 Oct 2. doi: 10.1002/cjp2.146. [Epub ahead of print]

3.

Dissecting PARP inhibitor resistance with functional genomics.

Pettitt SJ, Lord CJ.

Curr Opin Genet Dev. 2019 Feb;54:55-63. doi: 10.1016/j.gde.2019.03.001. Epub 2019 Apr 5. Review.

PMID:
30954761
4.

PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer.

Chabanon RM, Muirhead G, Krastev DB, Adam J, Morel D, Garrido M, Lamb A, Hénon C, Dorvault N, Rouanne M, Marlow R, Bajrami I, Cardeñosa ML, Konde A, Besse B, Ashworth A, Pettitt SJ, Haider S, Marabelle A, Tutt AN, Soria JC, Lord CJ, Postel-Vinay S.

J Clin Invest. 2019 Mar 1;129(3):1211-1228. doi: 10.1172/JCI123319. Epub 2019 Feb 11.

5.

The shieldin complex mediates 53BP1-dependent DNA repair.

Noordermeer SM, Adam S, Setiaputra D, Barazas M, Pettitt SJ, Ling AK, Olivieri M, Álvarez-Quilón A, Moatti N, Zimmermann M, Annunziato S, Krastev DB, Song F, Brandsma I, Frankum J, Brough R, Sherker A, Landry S, Szilard RK, Munro MM, McEwan A, Goullet de Rugy T, Lin ZY, Hart T, Moffat J, Gingras AC, Martin A, van Attikum H, Jonkers J, Lord CJ, Rottenberg S, Durocher D.

Nature. 2018 Aug;560(7716):117-121. doi: 10.1038/s41586-018-0340-7. Epub 2018 Jul 18.

6.

Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer.

Brough R, Gulati A, Haider S, Kumar R, Campbell J, Knudsen E, Pettitt SJ, Ryan CJ, Lord CJ.

Oncogene. 2018 Oct;37(43):5701-5718. doi: 10.1038/s41388-018-0368-z. Epub 2018 Jun 18.

7.

Coupling bimolecular PARylation biosensors with genetic screens to identify PARylation targets.

Krastev DB, Pettitt SJ, Campbell J, Song F, Tanos BE, Stoynov SS, Ashworth A, Lord CJ.

Nat Commun. 2018 May 22;9(1):2016. doi: 10.1038/s41467-018-04466-4.

8.

The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells.

Barazas M, Annunziato S, Pettitt SJ, de Krijger I, Ghezraoui H, Roobol SJ, Lutz C, Frankum J, Song FF, Brough R, Evers B, Gogola E, Bhin J, van de Ven M, van Gent DC, Jacobs JJL, Chapman R, Lord CJ, Jonkers J, Rottenberg S.

Cell Rep. 2018 May 15;23(7):2107-2118. doi: 10.1016/j.celrep.2018.04.046.

9.

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance.

Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, Harrell MI, Menon M, Brough R, Campbell J, Frankum J, Ranes M, Pemberton HN, Rafiq R, Fenwick K, Swain A, Guettler S, Lee JM, Swisher EM, Stoynov S, Yusa K, Ashworth A, Lord CJ.

Nat Commun. 2018 May 10;9(1):1849. doi: 10.1038/s41467-018-03917-2.

10.

E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast Cancer.

Bajrami I, Marlow R, van de Ven M, Brough R, Pemberton HN, Frankum J, Song F, Rafiq R, Konde A, Krastev DB, Menon M, Campbell J, Gulati A, Kumar R, Pettitt SJ, Gurden MD, Cardenosa ML, Chong I, Gazinska P, Wallberg F, Sawyer EJ, Martin LA, Dowsett M, Linardopoulos S, Natrajan R, Ryan CJ, Derksen PWB, Jonkers J, Tutt ANJ, Ashworth A, Lord CJ.

Cancer Discov. 2018 Apr;8(4):498-515. doi: 10.1158/2159-8290.CD-17-0603.

11.

ATR Is a Therapeutic Target in Synovial Sarcoma.

Jones SE, Fleuren EDG, Frankum J, Konde A, Williamson CT, Krastev DB, Pemberton HN, Campbell J, Gulati A, Elliott R, Menon M, Selfe JL, Brough R, Pettitt SJ, Niedzwiedz W, van der Graaf WTA, Shipley J, Ashworth A, Lord CJ.

Cancer Res. 2017 Dec 15;77(24):7014-7026. doi: 10.1158/0008-5472.CAN-17-2056. Epub 2017 Oct 16.

12.

Modeling Therapy Resistance in BRCA1/2-Mutant Cancers.

Dréan A, Williamson CT, Brough R, Brandsma I, Menon M, Konde A, Garcia-Murillas I, Pemberton HN, Frankum J, Rafiq R, Badham N, Campbell J, Gulati A, Turner NC, Pettitt SJ, Ashworth A, Lord CJ.

Mol Cancer Ther. 2017 Sep;16(9):2022-2034. doi: 10.1158/1535-7163.MCT-17-0098. Epub 2017 Jun 15.

13.

Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells.

Nikkilä J, Kumar R, Campbell J, Brandsma I, Pemberton HN, Wallberg F, Nagy K, Scheer I, Vertessy BG, Serebrenik AA, Monni V, Harris RS, Pettitt SJ, Ashworth A, Lord CJ.

Br J Cancer. 2017 Jun 27;117(1):113-123. doi: 10.1038/bjc.2017.133. Epub 2017 May 23.

14.

Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells.

Pettitt SJ, Krastev DB, Pemberton HN, Fontebasso Y, Frankum J, Rehman FL, Brough R, Song F, Bajrami I, Rafiq R, Wallberg F, Kozarewa I, Fenwick K, Armisen-Garrido J, Swain A, Gulati A, Campbell J, Ashworth A, Lord CJ.

Sci Data. 2017 Mar 1;4:170020. doi: 10.1038/sdata.2017.20.

15.

piggyBac transposon-based insertional mutagenesis in mouse haploid embryonic stem cells.

Pettitt SJ, Tan EP, Yusa K.

Methods Mol Biol. 2015;1239:15-28. doi: 10.1007/978-1-4939-1862-1_2.

PMID:
25408399
16.

A genetic screen using the PiggyBac transposon in haploid cells identifies Parp1 as a mediator of olaparib toxicity.

Pettitt SJ, Rehman FL, Bajrami I, Brough R, Wallberg F, Kozarewa I, Fenwick K, Assiotis I, Chen L, Campbell J, Lord CJ, Ashworth A.

PLoS One. 2013 Apr 25;8(4):e61520. doi: 10.1371/journal.pone.0061520. Print 2013.

17.

The piggyBac transposon displays local and distant reintegration preferences and can cause mutations at noncanonical integration sites.

Li MA, Pettitt SJ, Eckert S, Ning Z, Rice S, Cadiñanos J, Yusa K, Conte N, Bradley A.

Mol Cell Biol. 2013 Apr;33(7):1317-30. doi: 10.1128/MCB.00670-12. Epub 2013 Jan 28.

18.

Isolation of homozygous mutant mouse embryonic stem cells using a dual selection system.

Huang Y, Pettitt SJ, Guo G, Liu G, Li MA, Yang F, Bradley A.

Nucleic Acids Res. 2012 Feb;40(3):e21. doi: 10.1093/nar/gkr908. Epub 2011 Nov 29.

19.

Genome-wide forward genetic screens in mouse ES cells.

Li MA, Pettitt SJ, Yusa K, Bradley A.

Methods Enzymol. 2010;477:217-42. doi: 10.1016/S0076-6879(10)77012-9.

PMID:
20699144
20.

Agouti C57BL/6N embryonic stem cells for mouse genetic resources.

Pettitt SJ, Liang Q, Rairdan XY, Moran JL, Prosser HM, Beier DR, Lloyd KC, Bradley A, Skarnes WC.

Nat Methods. 2009 Jul;6(7):493-5. doi: 10.1038/nmeth.1342. Epub 2009 Jun 14.

Supplemental Content

Loading ...
Support Center